Safety and Effectiveness of a New Typhoid Vaccine
Author Information
Author(s): van Damme Pierre, Kafeja Froukje, Anemona Alessandra, Basile Venere, Hilbert Anne Katrin, De Coster Ilse, Rondini Simona, Micoli Francesca, Qasim Khan Rana M., Marchetti Elisa, Di Cioccio Vito, Saul Allan, Martin Laura B., Podda Audino
Primary Institution: Center for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp
Hypothesis
The Vi-CRM197 conjugate vaccine will be safe and immunogenic in healthy adults.
Conclusion
The Vi-CRM197 vaccine is safe, well-tolerated, and highly immunogenic, making it suitable for further testing in endemic populations.
Supporting Evidence
- Vi-CRM197 induced higher antibody levels compared to the licensed control vaccine.
- All vaccines were well tolerated with mild to moderate local pain being the most common reaction.
- At least 95% of subjects vaccinated with Vi-CRM197 achieved seroconversion.
Takeaway
A new vaccine for typhoid fever was tested and found to be safe and effective, which is good news for protecting people, especially children, in areas where typhoid is common.
Methodology
The study involved randomized controlled trials comparing the new vaccine with a licensed polysaccharide vaccine in healthy adults aged 18 to 40.
Potential Biases
Potential bias in self-reported adverse events and the exclusion of certain demographics from the study.
Limitations
The study was conducted only in European adults, which may not reflect the vaccine's effectiveness in other populations.
Participant Demographics
Healthy adults aged 18 to 40, predominantly Caucasian, with a mean age of approximately 23 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website